Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus SBRT after palliative ablation in hepatocellular carcinoma
ChiCTR2500101405Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of envafolimab in hepatocellular carcinoma (HCC), sponsored by Union Hospital. Primary endpoint: Progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
envafolimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500101405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101405.